Hot Investor Mandate: Japan Private Equity Looking Globally for Therapeutics, Devices and Digital Medicine

31 Oct

A private equity firm based in Japan makes venture stage investments, with  a typical investment size of USD 3-5 million per company. The firm’s geographical focus is Asia, centered on Japan and Taiwan. However, the firm may consider companies in the US and Europe. The firm is actively seeking new investment opportunities.

In the life sciences, the firm will primarily focus on therapeutics, and is also interested in medical devices and digital medicine. The firm is interested in new technologies such as cell and gene therapies, but also considers investing in small molecules and biologics, as well as biosimilars and reformulated drugs. The firm will invest in any indication area. The firm invests in companies from the late preclinical stage through to Phase II.

The firm is usually a follow-on investor. For early stage opportunities, the firm prefers that the company has a clinical trial plan in place. While the firm is interested in international opportunities, they prefer that the company is interested in expanding into Japan or Taiwan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: